Damora Therapeutics is expected to report zero revenue and a consensus EPS loss of $0.38 for Q2 2026, with the stock currently trading at $29.50 compared to a $44.00 average analyst price target.
The primary focus for investors is the regulatory timeline for lead candidate DMR-001, specifically the anticipated Investigational New Drug (IND) application submission slated for the second half of 2026 according to company guidance.
Despite a significant earnings miss in Q1, the stock has surged nearly 670% over the past year as markets reward progress in its anti-mutCALR monoclonal antibody pipeline for blood disorders. Analysts from Jefferies and Wedbush recently issued bullish coverage, highlighting DMR-001’s potential to offer superior efficacy and more convenient dosing in treating myeloproliferative neoplasms.